Belgian Food and Staples Retail Stock News

ENXTBR:VGP
ENXTBR:VGPReal Estate

Assessing VGP (ENXTBR:VGP) Valuation After Recent Share Price Weakness

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...
ENXTBR:VIO
ENXTBR:VIOMetals and Mining

Assessing Viohalco (ENXTBR:VIO) Valuation After Investor Interest In Its Diversified Metals And Cables Operations

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Argenx Leadership Shift And Vyvgart Milestones Reshape Autoimmune Growth Story

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo Share Cancellation Reshapes Ownership As Valuation Gap Persists

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...
ENXTBR:SOLB
ENXTBR:SOLBChemicals

Solvay (ENXTBR:SOLB) Q1 Profit Of €26 Million Tests Loss-Making Narrative

Solvay (ENXTBR:SOLB) opened 2026 with Q1 revenue of €1.1 billion and basic EPS of €0.25, alongside trailing twelve month revenue of €4.6 billion and a basic EPS loss of €0.24, setting a mixed backdrop for the latest results. Over recent quarters the company has seen revenue range between €1.1 billion and €1.3 billion per quarter, with basic EPS moving from €0.78 in Q1 2025 through several smaller profits and a loss of €0.90 in Q4 2025 before rebounding in Q1 2026, leaving investors focused on...
ENXTBR:ABI
ENXTBR:ABIBeverage

Anheuser-Busch InBev (ENXTBR:ABI) Margin Stability Supports Bullish Long Term Growth Narratives

Anheuser-Busch InBev (ENXTBR:ABI) opened 2026 with Q1 revenue of US$15.3b and basic EPS of US$1.30, setting a clear benchmark for how the rest of the year might shape up for the brewer’s top and bottom lines. The company has seen quarterly revenue move from US$13.6b in Q1 2025 to US$15.3b in Q1 2026, while basic EPS shifted from US$1.08 to US$1.30 over the same period. This gives you a clean read on how sales and per share earnings are tracking through the cycle. With that backdrop, the...
ENXTBR:ARGX
ENXTBR:ARGXBiotechs

Is It Time To Reassess argenx (ENXTBR:ARGX) After Its Strong Multi Year Run?

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...
ENXTBR:XIOR
ENXTBR:XIORResidential REITs

A Look At Xior Student Housing (ENXTBR:XIOR) Valuation After Its Stronger First Quarter Results

Why Xior’s latest quarterly results matter for investors Xior Student Housing (ENXTBR:XIOR) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of €48.67 million and net income of €48.6 million, compared with €43.88 million and €41.95 million a year earlier. See our latest analysis for Xior Student Housing. Despite the stronger first quarter figures, the share price is at €27.6, with a 1 day share price return of 0.91% but a 1 year total shareholder return of...
ENXTBR:UMI
ENXTBR:UMIChemicals

Umicore Leadership Shakeup Puts Digital Transformation And Execution In Focus

Umicore (ENXTBR:UMI) has appointed Lily Liu as Chief Financial Officer and Executive Vice President. The company is also creating a new Chief Digital & Transformation Officer role to focus on digitalization and operational excellence. These leadership changes reflect a shift in how Umicore organizes its executive team and oversees transformation initiatives. For investors watching ENXTBR:UMI, the leadership reshuffle comes with the stock at €17.18 and a mixed return profile. The share price...
ENXTBR:ABI
ENXTBR:ABIBeverage

Dividend Hike and Board Refresh Could Be A Game Changer For Anheuser-Busch InBev (ENXTBR:ABI)

At its 29 April 2026 shareholder meeting, Anheuser-Busch InBev approved a €1.15 gross total dividend for 2025 and refreshed its board, appointing Fabrizio Freda and Miguel Patricio as directors alongside new Restricted Share Directors. Coupled with a planned US$600.00 million investment in U.S. manufacturing and workforce training, these moves highlight AB InBev’s focus on strengthening operations and supporting shareholder returns. Next, we’ll examine how AB InBev’s newly approved...
ENXTBR:AGS
ENXTBR:AGSInsurance

Ageas Tightens Grip On Belgium While Eyeing India Growth And Valuation

ageas (ENXTBR:AGS) has completed the acquisition of the remaining stake in AG Insurance, consolidating full ownership of its Belgian insurance business. The company has issued new and treasury shares to BNP Paribas Cardif, increasing its outstanding share capital and reshaping its shareholder base. ageas is accelerating expansion in India, aiming for a top 10 position through acquisitions and deeper bancassurance partnerships. For investors watching ENXTBR:AGS, these moves come as the share...
ENXTBR:TEXF
ENXTBR:TEXFReal Estate

3 European Dividend Stocks To Watch With Up To 5.9% Yield

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.
ENXTBR:UCB
ENXTBR:UCBPharmaceuticals

UCB Neurology Data Spotlight May Inform Long Term Valuation And Outlook

UCB (ENXTBR:UCB) is presenting new clinical and real-world data at the American Academy of Neurology Annual Meeting. The updates cover epileptic encephalopathies, prolonged seizures, and generalized myasthenia gravis. Key datasets focus on fenfluramine in Dravet and Lennox Gastaut syndromes and on zilucoplan and rozanolixizumab in myasthenia gravis. Additional findings address patient and caregiver quality of life, healthcare resource use, and treatment patterns. For investors following...
ENXTBR:009789111
ENXTBR:009789111Banks

Assessing BGL BNP Paribas (ENXTBR:009789111) Valuation After Its Latest Full-Year Earnings Update

BGL BNP Paribas (ENXTBR:009789111) has released its full year 2025 results, reporting net income of €514.5 million compared to €477.9 million a year earlier. This provides investors with fresh data to reassess the stock. See our latest analysis for BGL BNP Paribas. The share price is currently €89.0, and the flat short-term share price returns sit alongside a 1-year total shareholder return of 0.00%. This suggests recent earnings news may not yet have shifted market expectations in a clear...
ENXTBR:DEME
ENXTBR:DEMEConstruction

Assessing DEME Group (ENXTBR:DEME) Valuation After The Norse Wind Offshore Vessel Milestone

Norse Wind vessel puts DEME Group (ENXTBR:DEME) in focus DEME Group (ENXTBR:DEME) has drawn fresh investor attention after christening the Norse Wind, a new offshore wind installation vessel equipped with a 3,200-tonne crane and a hybrid power system. The ship is built to install larger next generation turbines and operate in harsher offshore conditions. Its hybrid setup targets more than 70% emission reductions. Norse Wind already carries long term contracts for major European offshore wind...
ENXTBR:KIN
ENXTBR:KINEntertainment

European Companies That May Be Trading Below Estimated Value

As European markets experience a boost in sentiment due to hopes of a shorter Middle East conflict, indices like the STOXX Europe 600 and Germany's DAX have shown notable gains. In this environment, identifying stocks that may be trading below their estimated value can offer opportunities for investors looking to capitalize on potential market inefficiencies.
ENXTBR:ONWD
ENXTBR:ONWDMedical Equipment

Onward Medical (ENXTBR:ONWD) Loss Deepens In H1 2025 Reinforcing Bearish Profitability Concerns

Onward Medical (ENXTBR:ONWD) has reported its FY 2025 first half with revenue of €1.2 million, a basic EPS loss of €0.47, and net income loss of €21.2 million, setting a clear tone for another year focused on growth over profitability. The company has seen revenue move from €0.2 million in the first half of 2024 to €1.5 million in the second half of 2024 and €1.2 million in the first half of 2025. Basic EPS has shifted between losses of €0.53, €0.32, and €0.47 over the same periods,...
ENXTBR:SYENS
ENXTBR:SYENSChemicals

Syensqo (ENXTBR:SYENS) Q4 EPS Loss Deepens And Tests Bullish Profitability Narrative

Syensqo (ENXTBR:SYENS) has wrapped up FY 2025 with fourth quarter revenue of €1,384 million and basic EPS of a €1.61 loss, while the trailing twelve months show revenue of €5,969 million and basic EPS of a €0.85 loss. Over recent quarters, revenue has moved from €1,662 million in Q4 2024 to €1,678 million in Q1 2025, €1,639 million in Q2 2025, €1,558 million in Q3 2025, and €1,384 million in Q4 2025, with EPS swinging between a €1.28 loss and a €0.49 gain before landing at a €1.61 loss this...